News

The Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who each have received a single periocular injection of AIV007

The option is a definitive step forward in the field of vitreoretinal surgery

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

Rationale for delving into this topic is the recent studies that have reported that active and healthy living can reduce IOP.

At the World Ophthalmology Congress in Vancouver, Canada, John D. Sheppard, MD, MMSc, FACS, presented data on perfluorohexyloctane ophthalmic solution in the treatment of dry eye. He sat down with Ophthalmology Times to discuss the topic in further detail.

According to a study by a team of Korean researchers, published in BMC Ophthalmology, investigators conducted a retrospective study to examine the prevalence and clinical characteristics of ocular allergy in glaucoma patients using brinzolamide 1.0%/brimonidine 0.2% fixed combination (BBFC), with and without concurrent β-blocker.

At the World Ophthalmology Congress in Vancouver, Canada, Mahnia Madan, OD, FAAO, presented a paper on the tolerability of cosmetic products on the ocular surface. She sat down with Ophthalmology Times to discuss the topic in further detail.

Investigators at the Faculty of Medicine at the University of Augsburg in Germany , found that in the eye of the mouse macrophages are already forming in the vitreous body in the embryonic stage.

Ophthalmologists can use OCT to find the early signs of disease

According to the company, the priority review voucher would be issued upon approval of OPGx-LCA5.

Pearls for implanting the port delivery device with ranibizumab.

PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA).

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

The team conducted a cross-sectional study from December 2016 to March 2024 in patients with acute infectious conjunctivitis

During a recent Ophthalmology Times Case-Based Roundtable discussion, Albert S. Khouri, MD, shared his pearls in proactive glaucoma management.

With many benefits, AI technology does have the potential to change the way practices work in the coming years, but it may require additional advancements in terms of relieving physician burnout and driving organization.

The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.

In a study, Australian ophthalmology and optometry researcher and Beatles fan Professor Stephen Vincent has analyzed John Lennon’s little-known, hit-and-miss use of contact lenses in the 1960s and found the Rock and Roll Hall of Famer was probably right when he theorized that his cannabis use helped them stay in place.

EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Stephen R. Russell, MD, discussed the 9-year data he presented at the American Society of Retina Specialists annual meeting for voretigene neparvovec-rzyl.

Eastern Kentucky University student Madison Carlisle experienced rapid vision loss until the team at UK HealthCare was able to unravel the source of her issues.

Sadda is the second person to serve as chair. The first chairholder was John Irvine, MD, who was appointed to the role in 2001.

Technologies continue to push retina surgical suites into the future